Alpha Cognition (NASDAQ:ACOG) Earns Buy Rating from Analysts at HC Wainwright

Equities researchers at HC Wainwright began coverage on shares of Alpha Cognition (NASDAQ:ACOG) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating and a $20.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 251.49% from the stock’s current price.

Alpha Cognition Price Performance

Shares of ACOG stock opened at $5.69 on Tuesday. The company has a market capitalization of $91.15 million, a price-to-earnings ratio of -2.22 and a beta of 2.50. The business has a 50 day moving average of $5.92. Alpha Cognition has a 52 week low of $4.66 and a 52 week high of $7.00.

Hedge Funds Weigh In On Alpha Cognition

A number of institutional investors and hedge funds have recently modified their holdings of ACOG. Solas Capital Management LLC bought a new position in Alpha Cognition in the fourth quarter valued at about $8,096,000. Sphera Funds Management LTD. purchased a new stake in shares of Alpha Cognition during the 4th quarter valued at about $3,652,000. Alyeska Investment Group L.P. bought a new position in shares of Alpha Cognition in the 4th quarter worth approximately $2,356,000. Altium Capital Management LLC purchased a new position in shares of Alpha Cognition in the fourth quarter worth approximately $1,620,000. Finally, Rosalind Advisors Inc. bought a new stake in Alpha Cognition during the fourth quarter valued at approximately $1,489,000.

Alpha Cognition Company Profile

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.